Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jessica M Heijdra"'
Autor:
Marjon H Cnossen, Frank W G Leebeek, Ron A A Mathôt, M Coppens, MJHA Kruip, S Polinder, K Fischer, R Liesner, K Fijnvandraat, Laura H Bukkems, PW Collins, P Chowdary, K Meijer, A Janssen, MH Cnossen, Jessica M Heijdra, Wala Al Arashi, Nico C B de Jager, Michael E Cloesmeijer, Christian M Zwaan, FWG Leebeek, RAA Mathôt, RYJ Tamminga, BAP Laros-van Gorkom, P Brons, SEM Schols, FJM van der Meer, HCJ Eikenboom, REG Schutgens, F Heubel-Moenen, L Nieuwenhuizen, P Ypma, MHE Driessens, CM Zwaan, I van Vliet, D Keeling, J Lock, HCAM Hazendonk, I van Moort, T Preijers, JM Heijdra, NCB de Jager, MCHJ Goedhart, LH Bukkems, W Al Arashi, ME Cloesmeijer
Publikováno v:
BMJ Open, Vol 12, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/1965d1889ddf4cbeb8a1d66664e6a252
Autor:
Jessica M. Heijdra, Ferdows Atiq, Wala Al Arashi, Quincy Kieboom, Esmee Wuijster, Karina Meijer, Marieke J. H. A. Kruip, Frank W. G. Leebeek, Marjon H. Cnossen, in collaboration with the OPTI‐CLOT Study Group
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 6, Pp n/a-n/a (2022)
Abstract Background Individuals with von Willebrand disease (VWD) require desmopressin testing because of interindividual response differences. However, testing is burdensome, while not all patients may need extensive testing. Objectives To provide v
Externí odkaz:
https://doaj.org/article/fef425826bc741c78576e14267ed4a79
Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial)
Autor:
Iris van Moort, Tim Preijers, Laura H Bukkems, Hendrika C A M Hazendonk, Johanna G van der Bom, Britta A P Laros-van Gorkom, Erik A M Beckers, Laurens Nieuwenhuizen, Felix J M van der Meer, Paula Ypma, Michiel Coppens, Karin Fijnvandraat, Roger E G Schutgens, Karina Meijer, Frank W G Leebeek, Ron A A Mathôt, Marjon H Cnossen, Marjon H. Cnossen, Frank W.G. Leebeek, Ron A.A. Mathôt, Marieke J.H.A. Kruip, Suzanne Polinder, Janske Lock, Hendrika C.A.M. Hazendonk, Iris Van Moort, Jessica M. Heijdra, Marie C.H.J. Goedhart, Wala Al Arashi, Nico C.B. De Jager, Laura H. Bukkems, Michael E. Cloesmeijer, Alexander Janssen, Rienk Y.J. Tamminga, Paul Brons, Saskia E.M. Schols, Jeroen C.J. Eikenboom, Felix J.M. Van der Meer, Roger E.G. Schutgens, Kathelijne Fischer, Karin P.M. Van Galen, Erik E.A.M. Beckers, Floor C.J.I. Heubel-Moenen, Mariëtte H.E. Driessens, Ineke Van Vliet, Peter W. Collins, Ri Liesner, Pratima Chowdary, Carolyn M. Millar, Dan Hart, David Keeling
Publikováno v:
The Lancet Haematology, 8(7), e492-e502. Lancet Publishing Group
Lancet. Haematology, 8(7), e492-e502. Lancet Publishing Group
Lancet Haematology, 8, e492-e502
Lancet Haematology, 8(7), E492-E502. ELSEVIER SCI LTD
The Lancet Haematology, 8(7), E492-E502. ELSEVIER SCI LTD
Lancet Haematology, 8, 7, pp. e492-e502
Lancet. Haematology, 8(7), e492-e502. Lancet Publishing Group
Lancet Haematology, 8, e492-e502
Lancet Haematology, 8(7), E492-E502. ELSEVIER SCI LTD
The Lancet Haematology, 8(7), E492-E502. ELSEVIER SCI LTD
Lancet Haematology, 8, 7, pp. e492-e502
Contains fulltext : 237493.pdf (Publisher’s version ) (Closed access) BACKGROUND: Dosing of replacement therapy with factor VIII concentrate in patients with haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of f
Autor:
Jessica M, Heijdra, Michael E, Cloesmeijer, Nico C B, de Jager, Frank W G, Leebeek, Marieke H J A, Kruip, Marjon H, Cnossen, Ron A A, Mathôt
Publikováno v:
Haemophilia, 28(5), 814-821. Wiley-Blackwell
Haemophilia, 28(5), 814-821. Wiley-Blackwell Publishing Ltd
Haemophilia, 28(5), 814-821. Wiley-Blackwell Publishing Ltd
Introduction: Desmopressin can be used to prevent bleeding in von Willebrand disease (VWD), but the relationship between desmopressin and von Willebrand factor activity (VWF:Act) has yet to be quantified. Aim: To quantify the relationship between des
Autor:
Marjon H Cnossen, Frank W G Leebeek, Ron A A Mathôt, M Coppens, MJHA Kruip, S Polinder, K Fischer, R Liesner, K Fijnvandraat, Laura H Bukkems, PW Collins, P Chowdary, K Meijer, A Janssen, MH Cnossen, Jessica M Heijdra, Wala Al Arashi, Nico C B de Jager, Michael E Cloesmeijer, Christian M Zwaan, FWG Leebeek, RAA Mathôt, RYJ Tamminga, BAP Laros-van Gorkom, P Brons, SEM Schols, FJM van der Meer, HCJ Eikenboom, REG Schutgens, F Heubel-Moenen, L Nieuwenhuizen, P Ypma, MHE Driessens, CM Zwaan, I van Vliet, D Keeling, J Lock, HCAM Hazendonk, I van Moort, T Preijers, JM Heijdra, NCB de Jager, MCHJ Goedhart, LH Bukkems, W Al Arashi, ME Cloesmeijer
Publikováno v:
BMJ Open, Vol 12, Iss 2 (2022)
BMJ open, 12(2):e049493. BMJ Publishing Group
BMJ Open, 12(2):e049493. BMJ Publishing Group
BMJ open, 12(2):e049493. BMJ Publishing Group
BMJ Open, 12(2):e049493. BMJ Publishing Group
IntroductionVon Willebrand disease (VWD) is a bleeding disorder, caused by a deficiency or defect of von Willebrand factor (VWF). In case of medical procedures or bleeding, patients are treated with desmopressin and/or VWF-containing concentrates to
Autor:
Marjon H. Cnossen, Jessica M. Heijdra, Quincy Kieboom, Frank W.G. Leebeek, Nico C B de Jager, Marieke J. H. A. Kruip, Ron A. A. Mathôt
Publikováno v:
Thrombosis and haemostasis, 120(10), 1407-1416. Schattauer GmbH
Thrombosis and Haemostasis, 120(10), 1407-1416. Georg Thieme Verlag
Thrombosis and Haemostasis, 120(10), 1407-1416. Georg Thieme Verlag
Objective Most von Willebrand disease (VWD) patients can be treated with desmopressin during bleeding or surgery. Large interpatient variability is observed in von Willebrand factor (VWF) activity levels after desmopressin administration. The aim of
Autor:
Marcel C. M. Pistorius, Jessica M. Heijdra, Nico C B de Jager, Frank W.G. Leebeek, Marjon H. Cnossen, Marieke J. H. A. Kruip, Ron A. A. Mathôt
Publikováno v:
Therapeutic drug monitoring, 42(6), 880-885. Lippincott Williams and Wilkins
Therapeutic Drug Monitoring, 42(6), 880-885. Lippincott Williams & Wilkins
Therapeutic Drug Monitoring, 42(6), 880-885. Lippincott Williams & Wilkins
Background: Desmopressin (D-amino D-arginine vasopressin: dDAVP) is used for the treatment of patients with hemophilia A and Von Willebrand disease. Studies on the rationale of dosing are scarce and mainly focus on the underlying causes of the vast d
Autor:
Charles R. M. Hay, Pratima Chowdary, Benjamin Bailiff, Mary Mathias, Jeanette Payne, Nicola Curry, Tine M. H. J. Goedhart, Marjon H. Cnossen, Jessica M. Heijdra, Sarah Mangles, Robert Campbell Tait, Karina Meijer, Frank W.G. Leebeek, Peter William Collins, Steve Austin, Ron A. A. Mathôt, Laura H. Bukkems, Karin Fijnvandraat, Bethan Myers, G. Evans
Publikováno v:
Thrombosis and Haemostasis, 120(5), 747-757. Georg Thieme Verlag
Thrombosis and haemostasis, 120(5), 747-757. Schattauer GmbH
Thrombosis and Haemostasis, 120(5), 747-757. GEORG THIEME VERLAG KG
Thrombosis and haemostasis, 120(5), 747-757. Schattauer GmbH
Thrombosis and Haemostasis, 120(5), 747-757. GEORG THIEME VERLAG KG
Background The currently published population pharmacokinetic (PK) models used for PK-guided dosing in hemophilia patients are based on clinical trial data and usually not externally validated in clinical practice. The aim of this study was to valida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2725ef1b451329b318ac247f4e9fa808
https://pure.eur.nl/en/publications/ab0d2602-2004-4fbd-a4b7-d10d7bf577ca
https://pure.eur.nl/en/publications/ab0d2602-2004-4fbd-a4b7-d10d7bf577ca
Publikováno v:
Drugs
Drugs, 77(14), 1531-1547. Adis
Drugs, 77(14), 1531-1547. Adis
Von Willebrand disease (VWD) is the most common inherited bleeding disorder with an estimated prevalence of ~1% and clinically relevant bleeding symptoms in approximately 1:10,000 individuals. VWD is caused by a deficiency and/or defect of von Willeb
Autor:
Nico C B, de Jager, Laura H, Bukkems, Jessica M, Heijdra, Carolien H C A M, Hazendonk, Karin, Fijnvandraat, Karina, Meijer, Jeroen, Eikenboom, Britta A P, Laros-van Gorkom, Frank W G, Leebeek, Marjon H, Cnossen, Ron A A, Mathôt, D, Keeling
Publikováno v:
Journal of Thrombosis and Haemostasis
Introduction Many patients with von Willebrand disease (VWD) are treated on demand with von Willebrand factor and factor VIII (FVIII) containing concentrates present with VWF and/or FVIII plasma levels outside set target levels. This carries a risk f